Affiliate disclosure: This post contains an affiliate link; the publisher may earn a commission from qualifying purchases.
Research-use-only notice: The Void Research products discussed here are intended for controlled in-vitro or laboratory research by qualified researchers. They are not for human or veterinary use, consumption, administration, diagnosis, treatment, cure, prevention, clinical application, food, supplements, cosmetics, or personal experimentation.
GLP-3 RT, GLP-2 TZ, and CAGRI occupy three very different places in current peptide and metabolic-research discussions. Although their shorthand names can make them look like variations within one product family, the underlying research compounds represent distinct signaling strategies: GLP-3 RT corresponds to retatrutide, a triple GIP/GLP-1/glucagon receptor agonist; GLP-2 TZ corresponds to tirzepatide, a dual GIP/GLP-1 receptor agonist; and CAGRI corresponds to cagrilintide, a long-acting amylin analogue.
That difference matters before a laboratory even gets to experimental design. A procurement team evaluating these materials should not simply compare product names, vial sizes, or headline purity percentages. It should distinguish molecular identity, receptor architecture, the maturity of the published scientific evidence, the regulatory status of the underlying compounds, and—critically—the documentation tied to the actual commercial research lot being considered.
Qualified research buyers looking at the Void Research catalog can review the Void Research BOOST30 research catalog and use promo code BOOST30 for up to 30% off. The promotion is secondary to documentation review: the more important question is whether the selected material can be connected to appropriate identity, purity, lot, analytical-method, and supporting quality records for the planned laboratory work.
This comparison therefore approaches GLP-3 RT, GLP-2 TZ, and CAGRI from a research-product and documentation perspective rather than as a personal-use comparison.
The short answer: GLP-3 RT, GLP-2 TZ, and CAGRI are not interchangeable research materials
At the highest level, the three compounds differ in the biological systems they are designed to engage.
GLP-3 RT, mapped by current independent catalog reviews to retatrutide, represents a triple-receptor research model involving GIP, GLP-1, and glucagon receptors. Retatrutide remains investigational as of September 2026. Eli Lilly has reported positive Phase 3 results from its TRIUMPH program, but Lilly also states that retatrutide has not yet received regulatory approval.
GLP-2 TZ corresponds to tirzepatide. Tirzepatide is a dual GIP and GLP-1 receptor agonist. Unlike retatrutide, tirzepatide has already crossed the regulatory-development threshold into approved pharmaceutical use for specific indications. That does not turn a research-supply vial from an independent commercial supplier into an approved medicine, however. A research material must still be assessed as the specific material, lot, and documentation being supplied. Published mechanistic literature characterizes tirzepatide as a dual GIP/GLP-1 receptor agonist with distinct signaling behavior at those receptors.
CAGRI corresponds to cagrilintide, an investigational long-acting amylin analogue. Current clinical-development records continue to list cagrilintide as an investigational medicine in ongoing or recently progressing programs, including the RENEW program.
That means a laboratory comparing these three should think in terms of triple incretin/glucagon receptor research, dual incretin receptor research, and amylin-pathway research, rather than viewing them as three versions of the same experimental tool.
A practical comparison
| Research material | Underlying compound | Primary research architecture | Development context as of September 2026 | Documentation question that matters most |
|---|---|---|---|---|
| GLP-3 RT | Retatrutide | GIP + GLP-1 + glucagon receptor agonism | Investigational; positive Phase 3 topline results reported, not yet approved | Does the lot documentation establish identity and distinguish it clearly from other GLP-coded products? |
| GLP-2 TZ | Tirzepatide | GIP + GLP-1 receptor agonism | Underlying pharmaceutical compound is approved for specific medical indications | Does the research-supply documentation identify the commercial lot rather than relying on pharmaceutical literature? |
| CAGRI | Cagrilintide | Long-acting amylin analogue research | Investigational | Is the CAGRI lot supported by compound-specific analytical documentation and traceable batch information? |
This table is useful as an orientation, but it should not be used to infer that one material is “stronger,” “better,” or more suitable for a personal outcome. In a laboratory context, suitability depends on the research question, model, assay design, control strategy, documentation requirements, and institutional procedures.
GLP-3 RT: what the retatrutide research model represents
Retatrutide has drawn substantial scientific attention because it combines agonism at three metabolic hormone receptors in one molecule: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor.
The major published Phase 2 study in the New England Journal of Medicine described retatrutide as an agonist of GIP, GLP-1, and glucagon receptors and evaluated it in a randomized clinical research program. That study established the triple-receptor architecture that makes retatrutide scientifically different from tirzepatide.
For a laboratory researcher, the important point is not the clinical outcome reported in that trial. It is the pharmacological architecture. Triple-receptor agonism introduces a different signaling model from dual GIP/GLP-1 agonism, and that distinction can materially affect how experimental hypotheses are constructed.
If a study is designed around receptor selectivity, pathway crosstalk, downstream signaling, comparative binding behavior, metabolic-cell models, or assay-response interpretation, treating GLP-3 RT as merely a “higher-numbered GLP product” would be scientifically inadequate.
The shorthand “GLP-3 RT” is a catalog label. The research identity should be established through the documentation accompanying the actual material.
An independent August/September 2026 review of Void Research’s public catalog maps GLP-3 RT to retatrutide and reports publicly inspectable certificate records associated with Void Research. That review also emphasizes a limitation that laboratories should preserve in their own quality systems: a certificate tied to one tested sample or lot does not automatically validate every other lot or every other product sold by the same supplier.
That is an important procurement principle. Supplier-level reputation does not substitute for lot-level evidence.
Retatrutide’s current research status has changed significantly in 2026
A current comparison needs to distinguish older Phase 2 literature from the more recent Phase 3 development picture.
The pivotal TRIUMPH-1 trial record now lists the study as completed, with primary completion in April 2026 and an actual enrollment of 2,335 participants.
Eli Lilly announced positive topline Phase 3 results from TRIUMPH-1 in May 2026 and additional positive results from TRIUMPH-2 and TRIUMPH-3 in July 2026. The company has stated that it plans regulatory submission activity after completing the necessary development package.
At the same time, Lilly explicitly continues to describe retatrutide as investigational and says it has not been approved by any regulatory agency.
For research-content accuracy, those facts should appear together. Saying only that retatrutide is “in trials” is now incomplete. Saying that it is “approved” would be incorrect.
The accurate September 2026 description is that retatrutide is an investigational triple GIP/GLP-1/glucagon receptor agonist with a substantially advanced clinical-development program and reported positive Phase 3 topline results, but no regulatory approval yet.
That development status is separate from the analytical quality of any GLP-3 RT research vial sold by a laboratory supplier.
GLP-2 TZ: the dual GIP/GLP-1 research model
Tirzepatide provides a useful comparison because its receptor profile is simpler than retatrutide’s but more complex than selective GLP-1 receptor agonism.
Peer-reviewed mechanistic research describes tirzepatide as a dual GIP and GLP-1 receptor agonist. Detailed receptor-signaling work has also characterized differences in its relative engagement and signaling properties across the GIP and GLP-1 receptors.
This makes GLP-2 TZ particularly relevant where an experimental question focuses on dual incretin signaling rather than triple GIP/GLP-1/glucagon signaling.
A researcher comparing GLP-2 TZ with GLP-3 RT should therefore ask a mechanistic question first:
Does the study require a dual GIP/GLP-1 model, or does it require the additional glucagon-receptor component represented by retatrutide?
That distinction is much more meaningful than comparing the catalog labels “GLP-2” and “GLP-3.”
The numerical shorthand should not be interpreted as an established scientific classification system in which GLP-3 is simply a more advanced version of GLP-2. They are vendor-facing product codes that point to different compounds.
A previously published Void Research comparison in the supplied content inventory specifically addresses the GLP-3 RT versus GLP-2 TZ distinction from a research-target perspective, which can provide useful background before moving into the three-way documentation analysis here. The URL inventory supplied for this campaign includes that article among the newest September 2026 pieces.
Approved pharmaceutical status does not validate a third-party research vial
Tirzepatide’s regulatory history creates an important source-literacy issue.
Because the underlying molecule is used in approved pharmaceutical products, a reader may mistakenly assume that any vial labelled GLP-2 TZ or tirzepatide has pharmaceutical equivalence.
That inference is not justified.
Regulatory approval attaches to specific approved drug products, manufacturers, formulations, manufacturing systems, quality controls, labeling, distribution frameworks, and approved uses. It does not automatically extend to independently sold research material simply because the label names the same active molecular entity.
For laboratory procurement, the relevant questions remain:
What material is actually being supplied?
What lot is it?
What does the certificate identify?
Which analytical method was used?
What result was reported?
Which laboratory generated the result?
Can the report identifier be independently checked?
Does the documentation apply to the exact lot being received?
That is why product literature and clinical literature should be treated as different evidence layers.
Clinical literature can establish what tirzepatide is and how the molecule has been studied. It cannot by itself establish the identity, purity, net content, sterility, endotoxin status, heavy-metal profile, or other analytical characteristics of a particular commercial research vial.
CAGRI: a different pathway entirely
CAGRI adds an especially useful contrast because cagrilintide does not belong to the same GIP/GLP-1 receptor-agonist architecture as tirzepatide or retatrutide.
Cagrilintide is a long-acting amylin analogue under investigation. Current trial records continue to describe it as investigational, including the RENEW program evaluating cagrilintide in people with overweight or obesity, with and without type 2 diabetes.
From a research-design perspective, that means the primary scientific distinction is not simply the number of receptors.
Retatrutide investigates coordinated agonism across GIP, GLP-1, and glucagon receptors.
Tirzepatide investigates dual GIP and GLP-1 receptor agonism.
Cagrilintide is centered on amylin biology.
That difference matters in pathway-focused experiments, receptor-expression studies, mechanistic comparisons, and literature interpretation.
For example, a paper reporting an effect associated with triple-receptor agonism cannot automatically be used as evidence about an amylin analogue. Likewise, cagrilintide research should not be summarized as if it were simply another GLP-1 receptor agonist.
A useful previously published article in the supplied inventory describes the distinction among triple, dual, and amylin pathway research without personal-use claims. That is one of the most contextually appropriate earlier pages to link from a three-way comparison because it gives readers the conceptual framework before they encounter lot-documentation details.
Why molecular literature and supplier documentation must remain separate
One of the most common mistakes in research-peptide content is collapsing two very different questions:
- What is known about the scientific compound?
- What is known about the specific material being sold?
The first question is answered by peer-reviewed literature, trial registries, regulatory records, and developer disclosures.
The second requires product-specific and preferably lot-specific documentation.
Suppose a peer-reviewed article demonstrates that a compound called retatrutide has a particular receptor profile. That supports the scientific description of retatrutide.
It does not prove that a vial labelled GLP-3 RT contains retatrutide.
To support that claim about the vial, the evidence needs to connect the commercial sample to that molecular identity.
Likewise, if a supplier certificate reports a high chromatographic purity result, that does not automatically prove every possible quality attribute. Purity, identity, net content, sterility, endotoxin, and heavy-metal testing answer different analytical questions.
The distinction is fundamental.
A technically strong research procurement process asks which claim each document actually supports rather than treating every certificate as a universal quality guarantee.
What a useful COA should help establish
A Certificate of Analysis is most useful when it functions as a traceability record rather than as a decorative trust badge.
At minimum, a laboratory reviewing GLP-3 RT, GLP-2 TZ, or CAGRI documentation should be able to determine the tested material’s identity, relevant batch or lot reference, testing laboratory, analytical method, reported result, report date, and any report or verification identifier provided by the laboratory.
The Void Research URL inventory includes multiple earlier publications dedicated to COA interpretation and analytical methods, including an article comparing HPLC purity, LC-MS identity, and net-content information. Those pages are useful background because these measurements should not be treated as synonyms.
HPLC purity is not the same as identity
High-performance liquid chromatography can be used to assess chromatographic composition and purity.
A reported HPLC percentage may indicate that a large proportion of detected chromatographic material corresponds to the principal peak under the method used.
That does not answer every possible identity question.
A material could theoretically display a clean chromatographic profile while still requiring orthogonal analytical evidence to establish that the principal component is the intended compound.
Identity testing answers a different question
Mass-spectrometric techniques can help assess molecular identity by comparing observed mass-related characteristics with those expected for the target compound.
For coded products such as GLP-2 TZ and GLP-3 RT, identity evidence is especially relevant because the commercial shorthand itself does not establish molecular composition.
Net content answers another different question
Identity tells you what a material appears to be.
Purity helps characterize the relative composition of the sample under a given analytical method.
Net-content analysis addresses the amount of target material present.
Those are separate analytical dimensions.
A laboratory should therefore avoid reducing a COA to a single “99.x%” number.
The strongest documentation is claim-specific
Consider four hypothetical statements:
“The sample was identified as retatrutide.”
“The chromatographic purity was reported as 99.8%.”
“The tested sample contained a measured quantity close to its labeled amount.”
“The tested sample passed a sterility assay.”
Each statement requires different evidence.
A mass-identification method would not automatically establish sterility.
An HPLC purity value would not automatically establish endotoxin status.
A sterility result would not establish molecular identity.
Net-content analysis would not establish chromatographic purity.
This is why a broader testing panel can be more informative than a single assay—but even a broad panel must still be tied to the correct lot and interpreted according to what each method actually measures.
Independent current coverage of Void Research reports a publicly inspectable COA archive containing third-party laboratory documentation and identifies GLP-3 RT, GLP-2 TZ, and CAGRI mappings in the catalog. Current third-party review material also reports that the public archive has grown beyond its earlier smaller set of documents and now includes provider-checkable records for multiple products.
That is a useful transparency signal, but it still should not be converted into a blanket statement that every product or every future lot is equivalent.
Lot matching should come before marketing claims
A research team can perform a simple documentation discipline check before accepting any certificate into its procurement file.
First identify the exact product and lot received.
Then identify the corresponding laboratory report.
Then verify whether the report names or otherwise clearly identifies the same material.
Then compare the lot, accession, report code, or other identifiers.
Then verify the report through the testing laboratory where a public verification system exists.
Only after those steps should the analytical results be entered into the laboratory’s internal procurement or quality record.
This approach helps prevent a common error: using an old or generic certificate because it has the correct compound name even though it cannot be linked to the current lot.
The principle applies equally to GLP-3 RT, GLP-2 TZ, and CAGRI.
Do not transfer evidence from one compound to another
The similarity of product naming can encourage another mistake: transferring documentation strength across a catalog.
If a GLP-3 RT lot has a detailed multi-assay report, that does not prove that a GLP-2 TZ lot received the same testing panel.
If a CAGRI certificate includes one analytical method, it does not establish that an unrelated peptide was tested the same way.
If one product has identity, purity, sterility, endotoxin, and heavy-metal data, researchers should not describe the entire supplier catalog as having those results unless the supplier or laboratory documentation supports that broader statement.
This is especially important in affiliate content, where broad phrases such as “eight-times tested” or “fully tested” can easily become more expansive than the underlying certificate evidence.
A careful publication should describe the specific published record rather than universalizing it.
Comparing research maturity: retatrutide, tirzepatide, and cagrilintide
The scientific evidence base also differs substantially among the three.
Tirzepatide has a large clinical and mechanistic literature and has progressed through regulatory approval. Its dual GIP/GLP-1 mechanism has been characterized in peer-reviewed pharmacology and clinical research.
Retatrutide has progressed from Phase 2 research into a mature Phase 3 development program. The 2023 New England Journal of Medicine Phase 2 publication remains an important peer-reviewed source for its triple-receptor architecture, while 2026 trial records and sponsor disclosures provide the current Phase 3 development status.
Cagrilintide remains investigational, with active development programs evaluating the amylin analogue both independently and in combination-development settings. Current ClinicalTrials.gov records show continued Phase 3 research activity.
Those differences influence how confidently particular statements can be made.
For tirzepatide, researchers can draw from a large body of published mechanistic and clinical evidence.
For retatrutide, the evidence base is now substantial but regulatory review is still ahead.
For cagrilintide, ongoing investigation remains a central part of its current status.
None of those evidence differences validates a particular third-party research vial.
A better way to compare these products for laboratory procurement
Instead of asking, “Which one is best?”, a research team can ask five more useful questions.
1. Which biological pathway matches the experiment?
Choose the molecular research model based on the hypothesis.
A triple GIP/GLP-1/glucagon receptor question points toward retatrutide-type research.
A dual GIP/GLP-1 question points toward tirzepatide-type research.
An amylin-pathway question points toward cagrilintide-type research.
This is a scientific-design question, not a consumer recommendation.
2. Is the supplier label mapped clearly to the underlying compound?
House labels can simplify storefront navigation but create ambiguity in scientific records.
Internal laboratory documentation should record both the supplier label and the underlying molecular identity where that identity is supported.
For example:
GLP-3 RT — supplier label; retatrutide — molecular identity.
GLP-2 TZ — supplier label; tirzepatide — molecular identity.
CAGRI — supplier shorthand; cagrilintide — molecular identity.
3. Is there lot-specific documentation?
A product page may remain online for months while inventory lots change.
The analytical record needs to follow the lot, not merely the webpage.
4. Are the analytical methods appropriate for the claims being made?
Identity, purity, quantity, sterility, endotoxin, and contaminant screening should remain distinct evidence categories.
5. Can the laboratory preserve the documentation for audit purposes?
A procurement record should ideally retain the product page snapshot or purchase record, lot identifier, COA, laboratory verification result where available, receiving record, and internal acceptance decision.
That creates a reproducible trail long after the live webpage changes.
Documentation depth matters more when product names are abbreviated
The GLP-2 TZ and GLP-3 RT naming convention illustrates why abbreviated commercial labels need supporting context.
Someone encountering “GLP-3 RT” without a product description might reasonably assume it refers to a particular class of GLP-1 analogue.
That would be incomplete.
The scientific meaning comes from the molecular mapping to retatrutide and its GIP/GLP-1/glucagon receptor activity.
Likewise, “GLP-2 TZ” is not a formal pharmacological category. Its relevant identity is tirzepatide and its dual GIP/GLP-1 receptor profile.
For content publishers, this means an article should introduce both terms together early rather than forcing readers to infer the mapping.
For laboratory records, it means internal procurement systems should avoid storing only the vendor shorthand.
A note on the term “GLP-3”
The shorthand “GLP-3 RT” should not be confused with an official receptor nomenclature suggesting the discovery of a universally recognized “GLP-3 receptor.”
Retatrutide is described in the scientific literature as an agonist of the GIP, GLP-1, and glucagon receptors.
The commercial shorthand is therefore best understood as a supplier-facing identifier for a triple-receptor research compound rather than a replacement for formal receptor terminology.
This clarification helps avoid propagating an inaccurate scientific label from storefront copy into technical writing.
Why current status matters in September 2026
Research-compound content can become outdated quickly.
A retatrutide article written in early 2025 might reasonably describe Phase 3 studies as ongoing.
A September 2026 article needs to acknowledge that several major Phase 3 milestones have since been reported.
At the same time, the absence of regulatory approval remains important. Lilly continues to warn that retatrutide is investigational.
Cagrilintide likewise remains in clinical development, with current Phase 3 trial records in the RENEW program.
Tirzepatide differs because approved pharmaceutical products already exist.
These status distinctions should be dated whenever possible because they can change.
The literature does not replace experimental controls
Another important point for qualified researchers is that published efficacy or pathway data should not be used as a substitute for controls in a new experiment.
Published literature provides a rationale.
It can suggest receptor targets, expected pathways, assay design considerations, relevant biomarkers, and known limitations.
But a new study still needs appropriate controls, validated methods, replicates, predefined endpoints, and interpretation within the limits of the chosen model.
This is particularly important when comparing compounds with different receptor architectures. Observed differences may reflect receptor expression in the model, concentration-dependent effects, experimental conditions, analytical sensitivity, or other design variables.
A triple agonist is not automatically expected to produce a simple “larger” version of a dual agonist response.
Biological signaling networks are not numerical product ladders.
Mid-article BOOST30 reminder
For qualified laboratories that have completed their documentation review and determined that a Void Research material is appropriate for a lawful research workflow, BOOST30 is the campaign code for up to 30% off.
The code should remain a procurement consideration rather than the basis for choosing a compound. Molecular fit, lot traceability, analytical documentation, institutional requirements, and lawful research use come first.
Shipping and international procurement require separate checks
Commercial availability should never be treated as proof of legal importability.
Where Void Research offers international shipping, research buyers remain responsible for determining whether the material can lawfully be imported, possessed, stored, and used in the destination jurisdiction.
Customs requirements may differ by country and material.
Duties, VAT or GST, customs brokerage, importer-of-record responsibilities, delays, inspection, refusal, or seizure can also affect international shipments.
A storefront accepting an address does not establish that local law permits the transaction.
Research teams should therefore separate three questions:
Can the supplier ship it?
Can the destination legally receive it?
Can the institution legally possess and use it for the planned research?
Those are not always the same answer.
Frequently asked questions
What is Void Research GLP-3 RT?
GLP-3 RT is a Void Research catalog label mapped in current independent catalog documentation to retatrutide. Retatrutide is a GIP, GLP-1, and glucagon receptor agonist under investigation. Current 2026 development reports include positive Phase 3 topline results, but retatrutide has not yet received regulatory approval.
What is GLP-2 TZ?
GLP-2 TZ is a catalog shorthand mapped to tirzepatide. Tirzepatide is a dual GIP and GLP-1 receptor agonist. Peer-reviewed mechanistic literature supports that receptor classification.
What is CAGRI?
CAGRI refers to cagrilintide, a long-acting amylin analogue in clinical development. Current Phase 3 records continue to describe cagrilintide as investigational.
Is GLP-3 RT simply stronger than GLP-2 TZ?
That is not a scientifically useful way to describe the distinction. Retatrutide and tirzepatide engage different receptor architectures. Retatrutide includes glucagon-receptor agonism in addition to GIP and GLP-1 receptor agonism, whereas tirzepatide targets GIP and GLP-1 receptors. Their comparison should be based on the biological question and experimental design rather than a numerical “GLP-2 versus GLP-3” hierarchy.
Is CAGRI another GLP-1 agonist?
No. Cagrilintide is an amylin analogue, so its primary research framework is different from the GIP/GLP-1 and GIP/GLP-1/glucagon architectures of tirzepatide and retatrutide.
Does a 99% purity result prove that a peptide is correctly identified?
Not by itself. Purity and identity are different analytical questions. Researchers should evaluate the analytical method and determine what the reported result actually establishes.
Does one COA validate every vial sold by a supplier?
No. A certificate supports the sample or lot represented by that certificate. Laboratories should match the relevant report to the material actually received.
Why does lot matching matter?
Commercial inventories change. The same product page may be used across multiple manufacturing or fulfillment lots. Lot matching helps ensure that the laboratory record corresponds to the material under evaluation rather than an earlier sample.
Can published retatrutide or tirzepatide studies validate a commercial research vial?
No. Scientific publications establish information about the studied compound and experimental populations. They do not establish the identity or analytical quality of an independently sourced research vial.
Is retatrutide approved now that Phase 3 results have been announced?
No. As of September 2026, Lilly continues to describe retatrutide as investigational and not approved by any regulatory agency. Positive Phase 3 results and regulatory approval are separate milestones.
Is cagrilintide approved?
Current trial records still describe cagrilintide as investigational.
Final perspective
GLP-3 RT, GLP-2 TZ, and CAGRI should be compared first as distinct research tools, not as competing consumer products.
GLP-3 RT maps to retatrutide and represents a triple GIP/GLP-1/glucagon receptor research architecture.
GLP-2 TZ maps to tirzepatide and represents dual GIP/GLP-1 receptor agonism.
CAGRI maps to cagrilintide and represents long-acting amylin-analogue research.
Their underlying evidence bases also sit at different stages. Tirzepatide is supported by an extensive body of research and approved pharmaceutical products. Retatrutide has progressed through major Phase 3 milestones but remains investigational. Cagrilintide remains under active clinical development.
For a laboratory buyer, however, scientific maturity is only one layer.
The next layer is supplier documentation.
A rigorous procurement process should establish the exact molecular identity of the catalog code, connect analytical documentation to the correct lot, distinguish identity from purity and net-content results, check other assay categories only where they were actually performed, preserve third-party verification records where available, and avoid extending one certificate’s conclusions to unrelated lots or products.
That approach makes the comparison more useful than a simple product ranking because it connects molecular science with real-world laboratory traceability.
Qualified research buyers who have completed those checks can review Void Research with BOOST30 and use BOOST30 for up to 30% off.
Void Research products discussed here are strictly for controlled in-vitro and laboratory research by qualified researchers. They are not for human or veterinary consumption, administration, diagnosis, treatment, clinical use, or personal experimentation.
Top comments (0)